| Respiratory Tract Diseases |
NCT01079039: Survey for Usage Rates of Pertussis Vaccines in the State of Wisconsin |
|
|
| Active, not recruiting | 4 | 12000 | US | | Sanofi Pasteur, a Sanofi Company | Pertussis | 02/15 | 06/16 | | |
NCT01731626: Pemetrexed Disodium and Cisplatin in Treating Patients Undergoing Surgery For Stage I-III Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 52 | US | cisplatin, CACP, CDDP, CPDD, DDP, pemetrexed disodium, ALIMTA, LY231514, MTA, laboratory biomarker analysis, positron emission tomography, FDG-PET, PET, PET scan, tomography, emission computed, fludeoxyglucose F 18, 18FDG, FDG, therapeutic conventional surgery | Roswell Park Cancer Institute, National Cancer Institute (NCI), Eli Lilly and Company | Stage IB Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | 04/11 | | | |
NCT01279798: Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L) |
|
|
| No Longer Available | N/A | | US | Lucanix® (belagenpumatucel-L), Lucanix | NovaRx Corporation | Non-small Cell Lung Cancer | | | | |
| | N/A | 20 | Europe | AVAPS-AE, AVAPS-AE mode of ventilator therapy | Philips Respironics | Chronic Obstructive Pulmonary Disease | 12/12 | 12/12 | | |
NCT01798914: Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder |
|
|
| No Longer Available | N/A | | US | Technosphere Insulin Inhalation Powder, Afrezza Inhalation Powder | Mannkind Corporation | Type 1 Diabetes, Type 2 Diabetes | 04/15 | 05/15 | | |
NCT02271139: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy |
|
|
| No Longer Available | N/A | | US | Alectinib | Genentech, Inc. | Non-Small Cell Lung Cancer | | | | |
NCT02230982: Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| No Longer Available | N/A | | RoW | nintedanib | Boehringer Ingelheim | Idiopathic Pulmonary Fibrosis | | | | |
| Active, not recruiting | N/A | 1500 | Canada | | McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR), GlaxoSmithKline, AstraZeneca, Pfizer, Boehringer Ingelheim, Novartis, Takeda, Merck Sharp & Dohme LLC, Almirall, SAS | COPD, Chronic Obstructive Pulmonary Disease | 12/22 | 12/22 | | |
NCT01632475: Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia |
|
|
| Active, not recruiting | N/A | 9 | RoW | Pneumostem®, Human umbilical cord blood-derived mesenchymal stem cells | Samsung Medical Center, Medipost Co Ltd. | Bronchopulmonary Dysplasia | 09/25 | 09/26 | | |